Literature DB >> 8132760

Deletions in the COL4A5 collagen gene in X-linked Alport syndrome. Characterization of the pathological transcripts in nonrenal cells and correlation with disease expression.

C Antignac1, B Knebelmann, L Drouot, F Gros, G Deschênes, M C Hors-Cayla, J Zhou, K Tryggvason, J P Grünfeld, M Broyer.   

Abstract

The type IV collagen alpha 5 chain (COL4A5) gene of 88 unrelated male patients with X-linked Alport syndrome was tested for major gene rearrangements by Southern blot analysis, using COL4A5 cDNA probes. 14 different deletions were detected, providing a 16% deletion rate in the COL4A5 gene in the patient population. The deletions are dispersed all over the gene with different sizes, ranging from 1 kb to the complete absence of the gene (> 250 kb) in one patient. In four patients with intragenic deletions, absence of the alpha 3 (IV) chain in the glomerular basement membrane was demonstrated by immunohistochemical studies. This finding supports the hypothesis that abnormalities in the alpha 5 (IV) chain may prevent normal incorporation of the alpha 3 (IV) chain into the glomerular basement membrane. Direct sequencing of cDNA amplified from lymphoblast mRNA of four patients with internal gene deletions, using appropriate combinations of primers amplifying across the predicted boundaries of the deletions, allowed us to determine the effect of the genomic rearrangements on the transcripts and, by inference, on the alpha 5 (IV) chain. Regardless of the extent of deletion and of the putative protein product, the 14 deletions occur in patients with juvenile-type Alport syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132760      PMCID: PMC294071          DOI: 10.1172/JCI117073

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Posttransplant anti-glomerular basement membrane nephritis in related males with Alport syndrome.

Authors:  C E Kashtan; R J Butkowski; M M Kleppel; M R First; A F Michael
Journal:  J Lab Clin Med       Date:  1990-10

Review 2.  Alport syndrome, basement membranes and collagen.

Authors:  C E Kashtan; M M Kleppel; R J Butkowski; A F Michael; A J Fish
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

3.  Localization of the Goodpasture epitope to a novel chain of basement membrane collagen.

Authors:  R J Butkowski; J P Langeveld; J Wieslander; J Hamilton; B G Hudson
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

4.  Intragenic deletions in 21 Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) families studied with the dystrophin cDNA: location of breakpoints on HindIII and BglII exon-containing fragment maps, meiotic and mitotic origin of the mutations.

Authors:  B T Darras; P Blattner; J F Harper; A J Spiro; S Alter; U Francke
Journal:  Am J Hum Genet       Date:  1988-11       Impact factor: 11.025

5.  Nephritogenic antigen determinants in epidermal and renal basement membranes of kindreds with Alport-type familial nephritis.

Authors:  C Kashtan; A J Fish; M Kleppel; K Yoshioka; A F Michael
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

6.  The structural genes for alpha 1 and alpha 2 chains of human type IV collagen are divergently encoded on opposite DNA strands and have an overlapping promoter region.

Authors:  R Soininen; M Huotari; S L Hostikka; D J Prockop; K Tryggvason
Journal:  J Biol Chem       Date:  1988-11-25       Impact factor: 5.157

7.  Mapping of Alport syndrome to the long arm of the X chromosome.

Authors:  C L Atkin; S J Hasstedt; L Menlove; L Cannon; N Kirschner; C Schwartz; K Nguyen; M Skolnick
Journal:  Am J Hum Genet       Date:  1988-02       Impact factor: 11.025

Review 8.  Genetics of classic Alport's syndrome.

Authors:  F A Flinter; J S Cameron; C Chantler; I Houston; M Bobrow
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

9.  Heterozygosity for a large deletion in the alpha 2(I) collagen gene has a dramatic effect on type I collagen secretion and produces perinatal lethal osteogenesis imperfecta.

Authors:  M C Willing; D H Cohn; B Starman; K A Holbrook; C R Greenberg; P H Byers
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  18 in total

1.  Genotype-phenotype correlation in X-linked Alport syndrome.

Authors:  Mir Reza Bekheirnia; Berenice Reed; Martin C Gregory; Kim McFann; Alireza Abdollah Shamshirsaz; Amirali Masoumi; Robert W Schrier
Journal:  J Am Soc Nephrol       Date:  2010-04-08       Impact factor: 10.121

2.  Alport syndrome caused by inversion of a 21 Mb fragment of the long arm of the X-chromosome comprising exon 9 through 51 of the COL4A5 gene.

Authors:  Jens Michael Hertz; Ulf Persson; Inger Juncker; Mårten Segelmark
Journal:  Hum Genet       Date:  2005-10-28       Impact factor: 4.132

3.  De-differentiation of primary human hepatocytes depends on the composition of specialized liver basement membrane.

Authors:  Michael Zeisberg; Kyle Kramer; Nazia Sindhi; Pradip Sarkar; Melissa Upton; Raghu Kalluri
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

4.  Personalized medicine in chronic kidney disease by detection of monogenic mutations.

Authors:  Dervla M Connaughton; Friedhelm Hildebrandt
Journal:  Nephrol Dial Transplant       Date:  2020-03-01       Impact factor: 5.992

5.  Glomerular expression of type IV collagen chains in normal and X-linked Alport syndrome kidneys.

Authors:  L Heidet; Y Cai; L Guicharnaud; C Antignac; M C Gubler
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  Cyclosporin therapy in patients with Alport syndrome.

Authors:  Marina Charbit; Marie-Claire Gubler; Michèle Dechaux; Marie-France Gagnadoux; Jean-Pierre Grünfeld; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

7.  Establishment by the rat lymph node method of epitope-defined monoclonal antibodies recognizing the six different alpha chains of human type IV collagen.

Authors:  Y Sado; M Kagawa; Y Kishiro; K Sugihara; I Naito; J M Seyer; M Sugimoto; T Oohashi; Y Ninomiya
Journal:  Histochem Cell Biol       Date:  1995-10       Impact factor: 4.304

8.  Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2.

Authors:  Vera Uliana; Elena Marcocci; Mafalda Mucciolo; Ilaria Meloni; Claudia Izzi; Carlo Manno; Mirella Bruttini; Francesca Mari; Francesco Scolari; Alessandra Renieri; Leonardo Salviati
Journal:  Pediatr Nephrol       Date:  2010-12-14       Impact factor: 3.714

9.  Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome.

Authors:  E Boye; G Mollet; L Forestier; L Cohen-Solal; L Heidet; P Cochat; J P Grünfeld; J B Palcoux; M C Gubler; C Antignac
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

10.  Detection of large deletion mutations in the COL4A5 gene of female Alport syndrome patients.

Authors:  Kandai Nozu; Rafal Przybyslaw Krol; Yasufumi Ohtsuka; Koichi Nakanishi; Norishige Yoshikawa; Yoshimi Nozu; Hiroshi Kaito; Kyoko Kanda; Yuya Hashimura; Yuhei Hamasaki; Kazumoto Iijima; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2008-06-27       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.